The pharmaceutical industry is ready to fall off a cliff — a “patent cliff.” Over the next few years, some of the world’s most popular and lucrative medicines will go off patent, and generic competition will siphon an estimate…
To get potentially lifesaving drugs to patients faster, the U.S. Food and Drug Administration is allowed to approve some drugs — those that address unmet medical needs — based on fewer trials than usual. But it turns out that…
With corporate earnings season in full swing — watch for McDonalds, along with Catepillar, Amazon and other — and with the Fed meeting on interest rates, the GDP estimate and housing numbers coming out — the week ahead is ex…
From Jan. 10 to 13, thousands of investment pros and corporate chiefs flocked to the St. Francis Hotel for standing-room-only annual health care conference hosted by JPMorgan Chase. But two other, smaller but just as interestin…
The FDA has approved Amgen’s osteoporosis drug denosumab for use by cancer patients with solid tumors whose disease has metastasized to their bones. The indication to prevent complications such as fractures and bone pain among …